ReviewF1000Research2019
Recent advances in therapies for onychomycosis and its management.
Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comparative Retrospective Evaluation of the Clinical and Mycological Efficacy of 69% Nitric Acid, 1064 nm Nd:YAG Laser, and Their Combination in the Treatment ofInfectious disease reports · 2025Article
- Biofilm development in three-dimensional models infected withMicrobiology spectrum · 2025Article
- Novel Therapeutic Approaches Emerging in the Field of Onychomycosis.Recent advances in anti-infective drug discovery · 2025Review
- Efficacy of Fractional Versus Fully Ablative CODermatology practical & conceptual · 2024Article
- Severe drug eruption from oral terbinafine for mild onychomycosis-A case report from family practice and literature review: "Just an innocent little pill?"SAGE open medical case reports · 2024Article
- On the Basis of Sex: Impact and Treatment of Toenail Onychomycosis in Female Patients.The Journal of clinical and aesthetic dermatology · 2023Review
- Linalool-Incorporated Synergistically Engineered Modified Liposomal Nanocarriers for Enhanced Transungual Delivery of Terbinafine against Onychomycosis.Materials (Basel, Switzerland) · 2023Article
- Membranolytic Activity Profile of Nonyl 3,4-Dihydroxybenzoate: A New Anti-Biofilm Compound for the Treatment of Dermatophytosis.Pharmaceutics · 2023Article
- Lasers' Q-switched treatment in skin and subcutaneous lesions - review.Postepy dermatologii i alergologii · 2023Review
- Investigation on Utility of Some Novel Terpenes on Transungual Delivery of Terbinafine for the Management of Onychomycosis.Dermatology practical & conceptual · 2022Review
- Fractional COLasers in surgery and medicine · 2022Article
- Synthesis and Evaluation of the Antifungal and Toxicological Activity of Nitrofuran Derivatives.Pharmaceutics · 2022Article
- Non-Dermatophyte Mold Dominated Onychomycosis in Patients Attending a Rank Higher Specialized Dermatology Clinic in Addis Ababa, Ethiopia.Clinical, cosmetic and investigational dermatology · 2022Article
- In Silico Drug Screening Based Development of Novel Formulations for Onychomycosis Management.Gels (Basel, Switzerland) · 2021Article
- Constant Voltage Iontophoresis Technique to Deliver Terbinafine via Transungual Delivery System: Formulation Optimization Using Box-Behnken Design and In Vitro Evaluation.Pharmaceutics · 2021Article
- Application of central composite design for the optimization of itraconazole loaded nail lacquer formulation.3 Biotech · 2021Article
- NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile.Medical mycology · 2020Article
- Onychomycosis: An Updated Review.Recent patents on inflammation & allergy drug discovery · 2020Review
- An Open Study to Evaluate Effectiveness and Tolerability of a Nail Oil Composed of Vitamin E and Essential Oils in Mild to Moderate Distal Subungual Onychomycosis.Skin appendage disorders · 2020Article
- A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis.Journal of fungi (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onychomycosis is the most common affliction of the nail. It may be caused by dermatophytes, yeasts, and non-dermatophyte molds. Traditionally, oral antifungal treatments have been used to treat the fungus, although they can be accompanied by side effects and drug interactions. Topical treatments provide an alternative modality, bypassing the systemic effects of oral drugs; recent research has centered on topical drug improvement and development. Physical and laser treatments are being used in conjunction with topicals, which may help penetrate the thick nail plate. In this review, techniques from all categories are outlined: both novel experimental approaches and progress and effectiveness of recently developed treatments. More long-term studies are required to determine the efficacy of various treatments, but cure rates are improved when patients adhere to treatments and follow preventative measures to avoid disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.